Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 March 2023 | Story Nonsindiso Qwabe | Photo Stephen Collett
Prof Francis Petersen_ UFS Official Opening 2023
Prof Francis Petersen outlined the strategic intent of Vision 130 during his official welcoming address.

The trajectory to 2034, when the university turns 130, is not a dream, but an exciting journey that we are working towards achieving. Painting a picture of the university of the future, UFS Rector and Vice-Chancellor, Prof Francis Petersen, welcomed staff in his official opening speech on the Bloemfontein Campus on Friday 17 February 2023.

2023 marks the starting point of Vision 130, a vision with bold ambitions that will lead us to the renewal, re-imagining, and repositioning of the UFS in 2034, Prof Petersen said.  “We are building on our strengths, achievements, and learnings of our past and, in particular, the past five years. The vision is driven by excellence, and we won’t compromise excellence. It is about excellence, but it is also about visibility as an institution, and it is about impact.”

What does the UFS look like in 2034?

Prof Petersen said ours will be a university of choice for exceptional students, exceptional academics, and exceptional support staff. We will be recognised and acknowledged by peers and society as a top-tier university in South Africa, specifically among the top five universities in South Africa and the top 600 globally.

“Remember, I said we have built on the past, specifically the past five years, to give us a foundation. Still, we need to use that foundation to be able to deliver those specific goals or activities or deliverables that we want to achieve. We will have to start now if we want to achieve this in 2034.”

The Rector outlined four goals towards achieving these commitments:

• Improving academic excellence, improving our reputation, and improving our impact.

• Promoting an environment of agility, flexibility, and responsiveness.

• Advancing a transformational institutional culture that demonstrates the values of the University of the Free State – a place where ideas are discussed, contested, improved, and implemented in a culture of civil, robust engagement.

• Promoting stewardship and the prioritisation of institutional resources for strategic intent, which include our people, our staff, and our students.

Understand how your space is connected to Vision 130

“This is about creating a culture of delivery and empowering everyone within the University of the Free State and the UFS community to contribute to the realisation of Vision 130. This is what I am asking of you within your own sphere of operation. I am asking for a renewed commitment from you to own that space that you operate in. To understand how your space is connected to Vision 130 and to share what I would call an unrelenting ambition to deliver on this vision.”

Watch recording of the 2023 Official Opening below:


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept